



Press release 2018-04-03

## **C-RAD signs strategic agreement to equip ZON-PTC, a MAASTRO CLINIC company, in Maastricht, Netherlands for Catalyst PT**

**C-RAD announced today that it is entering into a collaboration with the Zuid-Oost Nederland Protonen Therapie Centrum (ZON-PTC) located at and largely owned by MAASTRO CLINIC, to develop integration of its Catalyst PT system to the Mevion S250i Proton Therapy System. As part of the collaboration MAASTRO has ordered the Sentinel 4DCT and Catalyst PT system.**

C-RAD offers a specific version of its Catalyst System for use in proton and particle therapy – Catalyst PT. It is based on the patented Catalyst technology and software as well as the hardware are tailored for the application in this environment.

In a first step the Catalyst system will be installed on a Varian TrueBeam linear accelerator at MAASTRO CLINIC to train future proton therapy staff in the clinical application of surface tracking. It is expected that first patients are treated on the proton therapy vault by the end of this year.

The proton therapy treatment room is currently under construction. The customer decided for a compact accelerator developed by the US based company Mevion Medical Systems®. As part of the collaboration the team in Maastricht together with Mevion and C-RAD have agreed to implement a workflow that features a seamless workflow with continuous motion monitoring from initial patient setup, throughout x-ray imaging until the completion of each fraction. With the help of C-RAD Catalyst PT MAASTRO CLINIC and ZON-PTC will also be able to offer respiratory gated treatments to their patients.

“In Maastricht we want to become a world leader in proton therapy with a special focus on moving targets (lung cancer and breast cancer). Therefore, the Catalyst PT in combination with the Sentinel system on the CT scanner plays a crucial role in establishing this goal, says Geert Bosmans, PhD, Head of Proton Physics at ZON-PTC. With C-RAD we found a partner to implement and improve solutions for high-precision proton treatments.”

C-RAD products are distributed by the Dutch company AEP International B.V. AEP is responsible for sales and service for the C-RAD Sentinel and Catalyst product line as well as for the Cyrpa laser in the Benelux market. The company has more than 35 years of experience in sales and marketing of high-quality linear accelerator components, as well as representing many renowned RT brands in the Benelux area.

“We are very proud to be part of this collaboration between ZON-PTC, C-RAD, Mevion and AEP” says Guido Moonen, responsible account manager at AEP International B.V; “We are convinced that patients of ZON-PTC will greatly benefit from the advantages of Surface Image Guided Radiation Therapy.”





This order is of strategic importance for C-RAD and has a value of approx. 3 MSEK. The project is booked as order intake in the first quarter. The first system is installed in April 2018. The project is expected to be finalized by the end of the year.

“We are very much looking forward to work on this exciting installation with the team at MAASTRO and ZON-PTC. The customer and C-RAD have the understanding of the importance of having an integrated, seamless workflow.” says Tim Thurn, CEO and President of C-RAD AB, “I am certain that the concepts that have been and will be developed in this project give guidance for our future in the PT segment. The success underlines C-RAD’s position as a leading provider of cutting-edge solutions for radiation therapy ”

#### *About ZON-PTC:*

*ZON-PTC (the South East Netherlands- Proton Therapy Centre) is currently under construction in The Netherlands at the Maastricht Brightlands Health Campus and will start treating patients end of 2018 / beginning 2019. Because of the compact Mevion technology the centre is the first in Europe to be fully integrated into an existing radiotherapy centre, MAASTRO clinic. Please visit, [www.zonptc.nl](http://www.zonptc.nl)*

#### *About C-RAD*

*C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.*

*For more information on C-RAD, please visit <http://www.c-rad.com>*

#### **For further information:**

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email [investors@c-rad.com](mailto:investors@c-rad.com)

This information is information that C-RAD AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 10:45 CEST on April 3, 2018.